



HAINAN FREE TRADE PORT · ISLAND-WIDE CUSTOMS CLOSURE LIVE SINCE DEC 18, 2025

One Free Trade Port. Two ways to win.

Manufacturers cut total tax burden by up to 64%. Traders settle cross-border funds in hours and ship into Mainland China duty-free. Both run through Venturepharma's own GMP plants in Haikou.

01 Line 1 · For CDMO clients

02 Line 2 · For global traders

03 Product portfolio

04 Registered catalogue

05 How we work

06 Contact

15%

Corporate income tax
(vs 25% mainland)

0

Import duty · ~6,600
tariff lines

≥30%

Value-added = duty-free
into Mainland China

2h

EF Account cross-border
settlement

Venturepharma · venturepharmaglobal.com · api8@venturepharm.net

Where should your next plant be? The location math.

Hainan vs mainland China vs India vs Ireland, on the dimensions that decide a CDMO contract.

Dimension	Hainan (Venturepharma)	Mainland China	India	Ireland / Europe
Corporate income tax	15%	25%	15–25% (conditional incentives)	12.5% (IE) / ~30% (DE)
Import duty on raw materials	0 (duty-free entry)	~6.5% (API, MFN)	~7.5–10% (BCD)	~0–6.5%
Selling into Mainland China	Duty-free at ≥30% value-added	Domestic (no tariff)	Full China import duty	Full China import duty
Imported equipment	0 duty (~6,600 tariff lines)	Taxed	Conditional relief	Taxed
Top talent personal income tax	Capped at 15%	Up to 45%	~30%+ surcharges	40–50%
Bottom line	Lowest tax burden + direct China access	Baseline	Low labor, higher compliance cost	Very high labor cost

※ Indicative comparison based on published standard rates. Actual figures vary by product, park and treaty.

A number you can verify yourself: peptide API outsourcing, \$10M/year

Scenario: tirzepatide side-chain & API project | imported raw materials \$5M/year (fatty diacids, protected amino acids) | 20% margin (\$2M profit)

Item	Mainland China plant	Hainan (Venturepharma)	Savings
Import duty on materials	\$5M × 6.5% = \$325K	\$0 (duty-free entry; duty-free into mainland at ≥30% value-added)	\$325K
Corporate income tax	\$2M × 25% = \$500K	\$2M × 15% = \$300K	\$200K
Equipment (one-off \$2M)	~\$2.3M taxed	\$2.0M duty-free	\$300K
Annual total (operating)	\$825K/yr	\$300K/yr	Save \$525K/yr (–64%)

💡 **For your CFO in one sentence:** same GMP-grade peptide API, and the Hainan route frees up \$525K per year. Pass it on in your pricing, or reinvest it in tighter quality systems. Over a 5-year contract: **\$2.62M**.

※ Indicative estimate. Actual savings depend on product, material mix and value-added ratio. Send us your target molecule for a project-specific calculation.

Cash in hours. China access duty-free. Tax stays low.

1 Getting goods into Mainland China: same cargo, three routes, three costs

Scenario: a European trader has \$1M worth of CoQ10 and other nutraceutical ingredients to sell into Mainland China

Route	Tariff	Customs / compliance	Verdict
① Direct import into Mainland China	~\$65–80K (6.5–8%) + 13% VAT	Shipment-by-shipment clearance, food-ingredient checks	Baseline
② Bonded zone processing	Tariff due on domestic sale	Manual-led regime, cumbersome domestic-sale procedures	Small savings, heavy admin
③ Hainan value-added route (Venturepharma)	\$0 (duty-free into mainland at ≥30% value-added)	Filing-based; direct entry via "Line 2"	Save \$65–80K per batch

💡 Route ③ saves \$65–80K per batch. The value-adding (refining, blending, repacking) happens in our own plant, so **the tariff saving and the processing service come as one single contract**. At ten batches a year, that is \$650–800K saved annually.

2 Getting paid: a EUR-denominated invoice settled in hours, not days

Scenario: a German distributor pays a \$500K invoice

Method	Settlement time	FX / paperwork
Traditional cross-border transfer (ordinary account)	1–2 business days	Document-by-document review; FX conversion via CNY
Hainan EF Account (instruction-based)	2–3 hours	USD/EUR/JPY multi-currency direct settlement, offshore rate of choice, fully online

💡 Cash that arrives a day earlier means an extra working-capital turn each year. As of Oct 2025, EF Account cumulative flows exceed **¥250 billion (~\$35B)** across 80 countries and regions.

3 Global re-export: goods enter free, leave free, or enter China duty-free

Scenario: an Asian buyer wants a regional node for European raw materials

Leg	Hainan model	Effect
Europe → Hainan ("Line 1")	Duty-free entry, bonded warehousing	No tariff capital locked up
Hainan → worldwide (re-export)	Free exit; value-adding (repacking, labeling) in Hainan; RCEP/ASEAN markets enjoy preferential treaty tariffs	Flexible distribution, closer to customers
Hainan → Mainland China ("Line 2")	≥30% value-added → duty-free	Switch to domestic sales anytime

💡 Hainan works as a duty-free pharma warehouse: **goods enter free, re-export free, and enter Mainland China duty-free**.

EF Account · Multifunctional Free Trade Account

CHINA'S QUASI-OFFSHORE, MULTI-CURRENCY ACCOUNT SYSTEM, DESIGNED FOR HAINAN

Transfers between the EF Account and overseas / OSA / NRA accounts move **on payment instruction alone**. Capital-account transactions (except securities investment) are **exempt from foreign-debt quotas and offshore-lending approvals**. As of Oct 2025: 11 banks live, cumulative flows over ¥250 billion.

2–3 hours

Cross-border settlement
(previously 1–2 days)

¥250B+

Cumulative flows across 80
countries

Multi-ccy

USD / EUR / JPY offshore rate
settlement

No approval

Capital account exempt from
quota & approval limits

※ Policy basis: GACC Announcement No. 158 of 2025 (value-added duty-free measures), Cai Guan Shui [2025] No. 12, and PBOC EF Account rules. Route ① tariff depends on specific HS code.

03 PRODUCT PORTFOLIO

Recommended products, matched to your role

Fifty selected items across five tables. The full 100+ item catalogue is available on request.

How to use: CDMO clients: pick items from Tables A/B/C and send us the CAS numbers for a quote. Traders: pick cargo from Tables D/E and we design your re-export or duty-free routing.

A · Peptide / GLP-1

Table A · Peptide / GLP-1 Platform (CDMO first choice · the hottest global track · 10 items)			
Product	CAS	Global traction	Hainan advantage
Semaglutide	910463-68-2	\$36.1B global sales 2025; China compound patent expired Mar 20, 2026; 10+ applicants already in queue	Side-chain imported → coupled in Hainan; value-added naturally ≥30%
Tirzepatide	2023788-19-2	The world's best-selling drug of 2025	Same route; C20 diacid side-chain integrated
Liraglutide	204656-20-2	\$2B+ global; China VBP volume	C16 side-chain refining + coupling
Orforglipron	2146797-44-2	First oral small-molecule GLP-1, launching 2026	Complex heterocycle synthesis; scale-up window open
Semaglutide side-chain NHS ester	1118767-15-9	Core of China's \$3.25B (+47.4%) peptide-API imports	Long-chain diacid imported → synthesized in Hainan → duty-free nationwide
Octadecanedioic acid mono-tert-butyl ester	843666-40-0	Key GLP-1 side-chain building block (shared by sema/tirze)	Crude imported → refined in Hainan → export + domestic

Table A · Peptide / GLP-1 Platform (CDMO first choice · the hottest global track · 10 items)			
Eicosanedioic acid mono-tert-butyl ester	-	Tirzepatide-specific C20 side-chain block	Co-line with C18, integrated cost-down
Fmoc-AEEA-OH (PEG linker)	166108-71-0	Universal PEG linker for GLP-1 & ADC	Purity upgrade + repacking, dual market
Leuprolide	53714-56-0	Peptide hormone, \$2B+ global	SPPS; China peptide-hormone exports +81.7%
Octreotide	83150-76-9	Acromegaly / NET essential	Cyclic peptide synthesis, protected-AA suite

B · ADC & Specialty

Table B · High-Potency (ADC) & Specialty Small Molecules (20 items · HPAPI capacity is nationally scarce)		
Product	CAS	Notes & Hainan advantage
MMAE (ADC payload)	646143-52-4	High-potency payload; OEB5 line (OEL ≤ 1 µg/m³); scarce capacity plus duty-free equipment, a double saving
SN-38	86639-52-3	Exatecan-class payload; ICH M7 genotoxic impurity control built in
Osimertinib	1421373-65-0	1L lung cancer blockbuster, strong China volume
Palbociclib	571190-30-2	CDK4/6, \$5B class
Abemaciclib	1231929-97-7	Lilly CDK4/6, \$4B class
Venetoclax	1257044-40-8	BCL-2, \$3B class; hematology essential
Ibrutinib	936563-96-1	BTK, \$9B class
Zanubrutinib	1691248-65-6	BeiGene's global flagship, scaling worldwide
Enzalutamide	915087-33-1	Prostate cancer, \$6B class
Apalutamide	956104-40-8	J&J prostate cancer growth
Upadacitinib	1310726-60-3	JAK inhibitor, \$5B class
Baricitinib	1187594-09-7	Lilly JAK, \$3B class
Tofacitinib	477600-75-2	The original JAK, global volume
Dapagliflozin	461432-26-8	SGLT2 blockbuster; patent-cliff volume; chiral C-glycoside route
Empagliflozin	864070-44-0	SGLT2, \$7B class
Rivaroxaban	366789-02-8	DOAC \$8B class; tight mainland supply; ship from Hainan
Apixaban	503612-47-3	DOAC \$12B class
Brivaracetam	357336-20-0	Epilepsy rising star; chiral pyrrolidone chemistry
Ramelteon	196597-26-9	Insomnia; chiral cyclanone intermediate
Tafamidis	594839-88-0	ATTR-CM blockbuster; low competition, high margin

C · Nutraceutical Refining

Table C · Nutraceutical Ingredient Refining (12 items · "crude in → Hainan value-added → duty-free into Mainland")		
Ingredient	CAS	Hainan value-added model
Coenzyme Q10 (high purity)	303-98-0	Crude import → recrystallization + softgel; value-added easily ≥30%
Astaxanthin (microalgae)	472-61-7	Import → microencapsulation → Mainland + US/Japan dual channel
DHA / EPA (fish oil)	6217-54-5 / 10417-94-4	Crude fish oil → molecular distillation → high-purity domestic sales
Melatonin	73-31-4	Imported raw → dosage-form processing (mind compliance path)
GABA	56-12-2	Import → blend & dosage form
L-Carnitine	541-15-1	High-purity import → blending; weight-management category
Ergothioneine	497-30-3	Japanese patented strain source → Hainan blending; beauty-from-within hit
PQQ	122628-50-6	Mitochondrial nutrition rising star → dosage form
Lactoferrin / β-Glucan	-	NZ/NL/US import → repack & blend; immunity category
Glucosamine / Chondroitin / MSM	-	US/AU import → joint-health sets, duty-free into Mainland
Grape-seed OPC / Curcumin (standardized)	-	FR/IN import → standardized extraction & blending
5-MTHF / Vitamin D3-K2 / Lutein ester / Collagen peptides	-	EU/US import → softgel / dropper / beauty-from-within OEM

D · Re-export Cargo

Table D · Traders: Re-export / Distribution Cargo (5 groups · zero-tariff in & out + EF settlement)		
Cargo	Flow	Trading advantages
Peptide side-chains / protected amino acids / Fmoc blocks	Europe/India ↔ Hainan ↔ nationwide	Two-way distribution node; multi-currency offshore rate hedging; bonded warehousing with zero tariff cash lock-up
Nutraceutical ingredients (astaxanthin, fish oil, CoQ10, OPC, ergothioneine, PQQ...)	Global ↔ Hainan ↔ Mainland China	Duty-free entry; ≥30% value-added = duty-free into Mainland; worldwide re-export (RCEP preferential tariffs)
High-end pharma intermediates	Global ↔ Hainan	Bonded repacking/labeling, then re-export; EF settlement in 2 hours
Finished specialty APIs (peptide / oncology)	Hainan → worldwide	Synthesized in Hainan → exported; peptide-hormone export track +81.7%; export-license compliance handled
Delivery devices & packaging components	Global ↔ Hainan	Injection pens, cartridges, silicone parts duty-free into Hainan, bundled with formulation exports

E · China Entry

Table E · Traders: The Hainan Route into Mainland China (duty-free corridor service · 3 groups)		
Your product	Route	What we deliver

Table E · Traders: The Hainan Route into Mainland China (duty-free corridor service · 3 groups)		
Overseas nutraceutical ingredients	Direct-to-mainland → rerouted via Hainan	Refining/blending in Hainan (≥30% value-added) → duty-free into Mainland; save 6.5–8% tariff
Pharma intermediates	Hainan value-added processing	Purification, polymorph upgrade, repacking: value-added and duty-free in one step
Your China warehouse	Hainan bonded warehousing	Duty-free storage, dispatch on demand: domestic via "Line 2", export via "Line 1"

04 REGISTERED CATALOGUE

Registered products: 72 items, ready to ship

Note: 55 APIs (incl. Nicotine, in development) and 17 intermediates. Quality standard: CP2020 = Chinese Pharmacopoeia 2020; In-house = internal corporate standard; "CDE filing in progress" = China DMF registration underway.

Active Pharmaceutical Ingredients (55 items · incl. Nicotine · in development)		
Product Name	Quality Standard	Certification
Adapalene	In-house	GMP
Repaglinide	CP2020	GMP
Adefovir Dipivoxil	CP2020	GMP
Voriconazole	CP2020	GMP
Cilostazol	CP2020	GMP
Loratadine	CP2020	GMP
Desloratadine	In-house	GMP
Fexofenadine Hydrochloride	In-house	GMP
Terbinafine Hydrochloride	CP2020	GMP
Lacidipine	In-house	GMP
Loperamide Hydrochloride	CP2020	GMP
Bisoprolol Fumarate	CP2020	GMP
Fluoxetine Hydrochloride	CP2020	GMP
Bupropion Hydrochloride	CP2020	GMP
Riluzole	CP2020	GMP
Zolmitriptan	CP2020	GMP
Letrozole	In-house	GMP
Trimetazidine Dihydrochloride	CP2020	GMP
Levetiracetam	CP2020	GMP

Active Pharmaceutical Ingredients (55 items · incl. Nicotine · in development)		
Memantine Hydrochloride	In-house	GMP
Carbocisteine	CP2020	GMP
Ritonavir	In-house	GMP
Zidovudine	CP2020	A
Nevirapine	CP2020	A
Lamivudine	CP2020	A
Stavudine	CP2020	A
Indinavir Sulfate	In-house	A
Citalopram Hydrobromide	CP2020	A
Eplerenone	CP2020	A
Telmisartan	CP2020	A
Fluconazole	CP2020	A
Metformin Hydrochloride	CP2020	A
Chlorpheniramine Maleate	CP2020	A
Carbamazepine	CP2020	A
Mannitol Nitrate	In-house	A
Inositol Nicotinate	In-house	A
Sulfamethoxazole	CP2020	A
Bisacodyl	CP2020	A
Meloxicam	CP2020	A
Monoclofenacic Acid	CP2020	A
Aripiprazole	In-house	GMP
Paroxetine Hydrochloride	In-house	GMP
Escitalopram oxalate	In-house	A
Olanzapine	In-house	A
Rivastigmine Hydrogen Tartrate	In-house	GMP
Agomelatine	In-house	CDE filing in progress
Amisulpride	In-house	CDE filing in progress
Bilastine	In-house	CDE filing in progress
Blonanserin	In-house	CDE filing in progress
Febuxostat	In-house	CDE filing in progress
Lacosamide	In-house	CDE filing in progress

Active Pharmaceutical Ingredients (55 items · incl. Nicotine · in development)		
Lurasidone hydrochloride	In-house	CDE filing in progress
Levomilnacipran	In-house	CDE filing in progress
Pimavanserin	In-house	CDE filing in progress
Safinamide mesylate	In-house	CDE filing in progress
Atomoxetine hydrochloride	In-house	CDE filing in progress
Nicotine	–	In Development

Intermediates (17 items)		
Product Name	CAS	Remarks
N-Methyl Desloratadine	38092-89-6	Intermediate for loratadine / desloratadine / rupatadine
4-Bromo-2,2-diphenylbutyric acid	37742-98-6	Loperamide intermediate
4-(4-Chlorophenyl)-4-hydroxypiperidine	39512-49-7	Loperamide intermediate
N-(3-Hydroxyphenyl)cinnamamide	23478-25-3	Brexiprazole intermediate
(E)-N-(3-Methyl-phenyl)-3-Phenyl-Acrylamide	151141-41-3	Brexiprazole intermediate
(1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one	96847-53-9	Levomilnacipran intermediate A
(1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide	172015-99-5	Levomilnacipran intermediate B
2-(1-Adamantanyl)-4-BromoAnisole	104224-63-7	Aripiprazole intermediate
2-(mercaptoethyl)-1,3-dioxybenzene	106308-60-5	Rupatadine intermediate
Triethyl phosphonoacetate	867-13-0	Istradefylline intermediate
(R)-dihydro-4-propylfuran-2(3H)-one	63095-51-2	Brivaracetam intermediate
2-[(E)-2-(Bromophenyl)vinyl]-4-chlorophenylacetate	1000890-04-9	Asenapine intermediate
N,N-diethyl-1-methylheptylpiperidine-4-carboxamide	6339-89-6	Lacosamide intermediate
3-(4-chlorophenyl)propan-1-ol	6282-88-8	Pitolisant intermediate
1-(1-Chloroethyl)-2,3-dimethylbenzene	60907-88-2	Dexmedetomidine intermediate
4-(3-Fluorophenoxy)benzaldehyde	66742-57-2	Safinamide intermediate
3-Fluorobenzyl chloride	456-42-8	Safinamide intermediate

Six steps: just bring the molecule

From molecule or cargo to market, one contract, one team.



Free starting point. CDMO clients: send a structure or CAS number, receive a feasibility review plus tax-savings calculation in 7 business days. Traders: send a cargo list, receive an EF Account funding plan plus duty-free routing design within 48 hours.

Audit-ready, every day



Send us your molecule or cargo list, get the numbers first

The tax-saving math arrives before the quotation. CDMO clients: feasibility review plus tax-savings sheet in 7 business days. Traders: EF Account funding plan plus duty-free routing design in 48 hours.

BUSINESS DEVELOPMENT

+86 13381191336 /
13976801327

EMAIL

api8@venturepharm.net

ADDRESS

No. 279 Nanhai Avenue,
Xiuying District, Haikou,
Hainan, China